The European Journal of Health Economics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
ConclusionsT-DXd is cost-effective based on surrogate WTP thresholds of €72,000 and €139,000 per QALY. (Source: The European Journal of Health Economics)
Source: The European Journal of Health Economics - July 24, 2023 Category: Health Management Source Type: research

Disclosing the ‘Big C’: what does cancer survivorship signal to employers?
AbstractTo study hiring discrimination against cancer survivors, we conduct a vignette experiment in which American and British professionals recruited via Prolific evaluate fictitious job candidates. Candidates differed by periods of non-employment in their career, including non-employment due to suffering from cancer. We study the effect of cancer experiences on professionals ’ hirability ratings, as well as its effect on underlying candidate perceptions, related to various potential forms of stigma identified in the literature. We find that employment opportunities are lower for candidates with a history of cancer, co...
Source: The European Journal of Health Economics - July 22, 2023 Category: Health Management Source Type: research

Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK
AbstractResidential care services are under increasing pressure to lower service provision costs while maintaining quality of care. Using a translog cost function, this paper examines the relationship between cost, quality and output in England ’s learning disability (LD) residential care sector. It finds genuine but diminishing economies of scale in LD residential care services vis-à-vis output (i.e., care weeks). However, some variation exists: higher-quality LD residential care homes appear to have larger economies of scale than lowe r-quality ones. Supplementary regression analysis, examining quality-size, further f...
Source: The European Journal of Health Economics - July 19, 2023 Category: Health Management Source Type: research

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
ConclusionEncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM. (Source: The European Journal of Health Economics)
Source: The European Journal of Health Economics - July 11, 2023 Category: Health Management Source Type: research

Factors associated with the author-reported cost-effectiveness threshold in high-income countries: systematic review and multivariable modelling
ConclusionsOur results underline the virtuous role of state recommendations in the choice of a low and homogeneous CET. We also highlight the need to integrate the a priori justification of the CET into good publishing guidelines. (Source: The European Journal of Health Economics)
Source: The European Journal of Health Economics - July 11, 2023 Category: Health Management Source Type: research

The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial
ConclusionBased on health insurance claims data, a significant reduction due to the home-based TeGeCoach program could not be found for health care use and costs in patients with PAD. Nevertheless, in all sensitivity analysis a tendency became apparent for a non-significant cost reducing effect.Trial registrationNCT03496948 (www.clinicaltrials.gov), initial release on 23 March 2018 (Source: The European Journal of Health Economics)
Source: The European Journal of Health Economics - July 10, 2023 Category: Health Management Source Type: research

The effect of duration and time preference on the gap between adult and child health state valuations in time trade-off
AbstractComposite time trade-off (cTTO) utilities have been found to be higher when adults value health states for children than for themselves. It is not clear if these differences reflect adults assigning truly higher utilities to the same health state in different perspectives, or if they are caused by other factors, which are not accounted for in the valuation procedure. We test if the difference between children ’s and adults’ cTTO valuations changes if a longer duration than the standard 10 years is used. Personal interviews with a representative sample of 151 adults in the UK were conducted. We employed the cTT...
Source: The European Journal of Health Economics - July 8, 2023 Category: Health Management Source Type: research

Competition and collaboration in health care: reconciling the irreconcilable? Lessons from The Netherlands
(Source: The European Journal of Health Economics)
Source: The European Journal of Health Economics - July 8, 2023 Category: Health Management Source Type: research